<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:660432515;
mso-list-template-ids:-693842958;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:932857026;
mso-list-template-ids:203310286;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2
{mso-list-id:1744066036;
mso-list-template-ids:1546268626;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:2013871748;
mso-list-template-ids:459697806;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/tbiphrp" target="_blank">Traumatic Brain Injury and Psychological Health Research Program</a><br>
<b>Clinical Research Development Award</b><br>
Pre-application (required preproposal): September 8. Full application: September 30.<br>
<b>Idea Development Award</b><br>
Pre-application (required preproposal): September 8. Full application: September 30.<br>
<b>Investigator Initiated Research Award</b><br>
Pre-application (required preproposal): September 8. Full application: September 30.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: September 20.</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<b>Clinical Trial Award</b><br>
Pre-application (required preproposal): September 15. Invited full application: December 16.<br>
<b>Focused Program Award</b> <br>
Pre-application (required preproposal): September 15. Invited full application: December 16.
<br>
<b>Translational Research Award</b><br>
Pre-application (required preproposal): September 15. Invited full application: December 16.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: December 6.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Sony Research Awards<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.sony.com/en/SonyInfo/research-award-program/#FacultyInnovationAward">Faculty Innovation Award</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Global research and development at Sony enables us to foster innovative ideas, which could ultimately lead to future technology advancements and company growth. In order to speed up and
expand the creation of new ideas, we would like to partner with universities. This partnership will help cultivate advanced concepts and fertilize our own research and development. The Sony Faculty Innovation Award provides up to $100K USD in funds to conduct
pioneering research in the areas of information technology, devices and materials, and
<b>biomedical and life science</b>: digital health around respiratory/heart sound analysis; behavioral change interventions / systems / theory in healthcare; MCI and early dementia assistive technology; speech patters / facial expressions / working memory;
cognitive ability / social interactions / behavior; remote and telemedicine.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">$100,000 for one year projects.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.sony.com/en/SonyInfo/research-award-program/#FocusedResearchAward">Focused Research Award</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Solid research is the underlying driving force to crystallize fearless creativity and innovation. While we are committed to run in-house research and engineering, we are also excited to
collaborate with academic partners to facilitate exploration of new and promising research. The Sony Focused Research Award provides an opportunity for university faculty and Sony to conduct this type of collaborative, focused research. The list of candidate
research topics includes intelligent sensing of patient reported outcomes.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">$150,000 for one year projects.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 16, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: September 2 (due to Labor Day holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://forefdn.org/wp-content/uploads/2021/07/Prevention_RFP_FINAL.pdf">Foundation for Opioid Response Efforts: Preventing Opioid Use Disorder and Overdose</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Foundation for Opioid Response Efforts (FORE) aims to convene and support partners advancing patient-centered, innovative, evidence-based solutions impacting people experiencing opioid
use disorder (OUD), their families, and their communities. To that end, FORE will provide grant support for specific projects that aim to improve, expand, and/or scale evidence-based family-, school-, and/or community-based prevention services for children
and families, particularly for those at highest risk. Applicants may apply for a grant of up to $500,000 per year for up to three years. This RFP targets projects that can develop, adapt, explore, and/or evaluate promising evidence-based models of family-
and community-based prevention for OUD and overdose. FORE is particularly interested in taking a holistic approach to the needs of every family member, recognizing that some may be in OUD treatment and/or recovery, while others would benefit from preventive
measures. FORE also is interested in community-based intervention approaches that meet children and families where they are, including within schools and “after school” activities and healthcare settings. Currently, this opportunity will focus on projects
in the following three areas which, based on discussions with experts in the field, are needed to improve prevention efforts in communities nationwide:<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">1. Mitigating the Impact of ACEs on Families</span></b><span style="font-size:12.0pt;font-family:Palatino">: Adverse childhood experiences (ACEs) and trauma play a significant role
in whether an individual is susceptible to developing a SUD. People with high ACE scores are more likely to start using drugs or alcohol at an early age and are up to ten times more likely to experience addiction than people who have not experienced childhood
trauma. Projects in this focus area include evidence-based prevention models that target children and families at the highest risk, including families who have a caregiver in treatment, recovery, or actively using substances.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">2. Developing Models for Racial and Cultural Minorities and Addressing Inequities</span></b><span style="font-size:12.0pt;font-family:Palatino">: In recent years, the gap in the rate
of opioid overdoses between racial minorities, such as Black and Latinx individuals and white Americans, has narrowed significantly. The nation’s “war on drugs” also has led to a disproportionate number of children in these communities growing up without a
parent present. Despite the pressing need, the presence of effective interventions in minority communities is limited. Projects in this focus area include developing culturally informed and inclusive prevention models that address health inequities, are effective
in diverse communities of color, and identify routes to successful sustainability.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">3. Addressing and Managing Pain, Emotional Distress, and Trauma</span></b><span style="font-size:12.0pt;font-family:Palatino">: Alleviating physical and/or emotional pain is a common
reason for initiating misuse of opioids and other substances. Projects that help children and adolescents develop healthy ways of responding to pain with interventions or supports that may be based in schools, homes, or communities will be considered.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Concept note due September 20, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: September 7.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.advanceresearchawards-chronicpain.com/">Pfizer: Global Awards for Advancing Chronic Pain Research (ADVANCE)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this competition is to fund innovative, novel research proposals that seek to advance the understanding and management of chronic pain. Areas of research that are considered <b>in-scope</b> for
an ADVANCE research grant, with the condition of interest being osteoarthritis (OA) and chronic pain associated with OA, will include studies that aim to advance the understanding of the following.<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Evaluation of unmet medical needs in pain management associated with OA as follows:<o:p></o:p></span></li><ul style="margin-top:0in" type="circle">
<li class="MsoNormal" style="mso-list:l0 level2 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Benefit-risk assessment and patient preference in the choice of pain medication for patients with comorbid conditions (e.g., cardiovascular disease or
history of substance abuse)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level2 lfo3"><span style="font-size:12.0pt;font-family:Palatino">How risks associated with long-term use of analgesics are assessed currently<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level2 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Treatment of chronic pain in special populations (e.g., postsurgical, elderly)<o:p></o:p></span></li></ul>
<li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Evaluation of multi-disciplinary approaches to management of OA (e.g., physical therapy, cognitive behavioral therapy) and their combination with pharmacological
treatment<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Understand and predict response to treatment, disease state, and course of OA (normal and rapid trajectories)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Approaches to improving adherence to therapy or therapeutic regimes for pain associated with OA<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Use of patient characteristics such as biomarkers or other objective evaluations (e.g., quantitative sensory testing , imaging modalities) in the assessment
and management of OA to better understand disease course<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Evaluation of improved function<o:p></o:p></span></li><ul style="margin-top:0in" type="circle">
<li class="MsoNormal" style="mso-list:l0 level2 lfo3"><span style="font-size:12.0pt;font-family:Palatino">How changes of physical function are assessed in clinical practice in patients with OA, and how current physical function assessment could be improved<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level2 lfo3"><span style="font-size:12.0pt;font-family:Palatino">How individual goal setting can contribute to treatment outcome (including pain and function)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level2 lfo3"><span style="font-size:12.0pt;font-family:Palatino">What impact the improved physical function has on the patients’ quality of life<o:p></o:p></span></li></ul>
</ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">A total of US $500,000 will be available to fund research proposals of up to US $150,000.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 22, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: September 9.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdn.pfizer.com/pfizercom/2021-07/GMG_2021-Oncology_Pre-clinicalTranslationalResearchMultipleMyeloma.pdf?UnRfpVUp54ppiJdAEQL4HUHwrLvuMhuY">Pfizer: Pre-clinical and Translational
Research in Multiple Myeloma</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Grants of up to $150,000 will be awarded in support of pre-clinical and translational research in multiple myeloma. Only pre-clinical projects with a focus on these areas of interest will
be considered: correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRDnegativity, and response to prior therapy; understanding the kinetics of sBCMA vs long-term responses (e.g., DoR, PFS,
OS) in the context of bispecific treatment; mechanisms of resistance (e.g., role of sBCMA in resistance/relapse; downregulation of membrane bound BCMA; T-cell exhaustion); correlation between soluble BCMA and BCMA expression on myeloma cells (including assessment
of gamma secretase activity); impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA levels (including whether these prior treatments lead to BCMA mutations); mechanistic understanding of the impact of anti-myeloma agents (e.g.,
IMiDs, anti-CD38, proteasome inhibitors, dexamethasone) on elranatamab-mediated T-cell activation and anti-myeloma activity; exploring in-vitro or in-vivo novel combinations with elranatamab (PF06863135) with a focus on drugs that are not currently SOC in
myeloma; immunosuppressive mechanisms in the bone marrow that negatively impact bispecific (elranatamab) activity; and comparative analysis of bone marrow aspirate transcriptomes between responders and non-responders to elranatamab. Studies can be in-vitro
or in-vivo or use existing patient samples (e.g., blood, bone marrow aspirates). A limited amount of the Pfizer asset elranatamab (PF-06863135) is available and can be requested through this RFP for non-clinical studies.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 28, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: September 15.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/oc/gap/">FSU Office of Commercialization: GAP Commercialization Investment Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Do you have a researcher within your department who has a commercially viable invention? Are you a member of the FSU research community currently working on new innovations that may have
value commercially? Would up to $50,000 in funding help you get your idea closer to commercialization of that product or idea? If you answered yes to any of these questions, the FSU GAP Commercialization Investment Program (GAP) may be for you! GAP is a competitive
investment program designed to help FSU Researchers move their research towards commercialization.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre<span style="color:#1F497D">-</span>proposals due September 23, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: September 13.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">FSU Council on Research and Creativity</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/cofrs/">Committee on Faculty Research Support (COFRS) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-review deadline: November 8, 2021, 4:59 p.m.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 18, 2021. <span style="color:red">Med-RA deadline to receive draft documents: November 4 (due do Veterans Day holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/eieg/">Equipment & Infrastructure Enhancement (EIEG) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-review deadlines:
</span></b><span style="font-size:12.0pt;font-family:Palatino">October 4, 2021, 4:59 p.m. and February 14, 2022 4:59 p.m.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 14, 2021 and February 24, 2022. <span style="color:red">Med-RA deadline to receive draft documents for October 14 deadline: October 4.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/fyap/">First Year Assistant Professor (FYAP) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">FYAP Workshop:
</span></b><span style="font-size:12.0pt;font-family:Palatino">September 10, 2021 (mandatory for submitters).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-review deadline: October 11, 2021, 4:59 p.m. </span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 21, 2021. <span style="color:red">Med-RA deadline to receive draft documents: October 11.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/mds/">Multidisciplinary Support (MDS) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-review deadline:
</span></b><span style="font-size:12.0pt;font-family:Palatino">January 24, 2021, 4:59 p.m.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 3, 2022. <span style="color:red">Med-RA deadline to receive draft documents: January 24.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/pg/">Planning Grant (PG) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-review deadlines:
</span></b><span style="font-size:12.0pt;font-family:Palatino">September 27, 2021, 4:59 p.m. and February 7, 2022, 4:59 p.m.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 7, 2021 and February 17, 2022. <span style="color:red">Med-RA deadline to receive draft documents for October 7 due date: September 27.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/sgp/">Small Grants Program (SGP)</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-review deadlines:
</span></b><span style="font-size:12.0pt;font-family:Palatino">October 4, 2021, 4:59 p.m. and February 28, 2022, 4:59 p.m.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 14, 2021 and March 10, 2022. <span style="color:red">Med-RA deadline to receive draft documents for October 14 due date: October 4.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.abbviemedicalresearch.com/external/AV_SPT_SiteLoginPage" target="_blank">AbbVie: Investigator-initiated studies</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of the Investigator-initiated Studies (IIS) Program is to support investigator-initiated research ideas that align with AbbVie’s defined
<a href="https://www.abbvie.com/partnerships/areas-of-interest.html">areas of strategic interest</a> (broadly: immunology, oncology, neuroscience, eye care, and aesthetics). The IIS program is not an unrestricted grant program, there are contractual obligations
tied to the receipt of any support for an IIS proposal. The research proposal must align with the company’s defined areas of strategic interest. Depending on each therapeutic area’s current interests, this may include:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Investigator-initiated studies involving
<a href="https://www.abbvie.com/partnerships/abbvie-ventures/portfolio.html">legacy Allergan and AbbVie products</a><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Non-interventional research, such as epidemiology or outcomes studies, where the focus is on scientific understanding of the disease<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">In vitro or animal studies<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Support provided by AbbVie may be in the form of product or funding, dependent on the type of research and availability of funds.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Applications accepted on a rolling basis.
<span style="color:red">Med-RA deadline to receive draft documents: 10 business days before submission to sponsor.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:#954F72">CoM’s
unofficial funding opportunities blog</span></b></a><b>.</b></span><o:p></o:p></p>
</div>
</body>
</html>